BidaskClub upgraded shares of Akero Therapeutics (NASDAQ:AKRO) from a hold rating to a buy rating in a research report report published on Saturday morning, BidAskClub reports.

A number of other equities analysts have also weighed in on the stock. Jefferies Financial Group boosted their price target on shares of Akero Therapeutics from $31.00 to $48.00 and gave the stock a buy rating in a research report on Wednesday, July 1st. HC Wainwright boosted their price target on shares of Akero Therapeutics from $45.00 to $62.00 and gave the stock a buy rating in a research report on Monday, July 20th. JPMorgan Chase & Co. boosted their price target on shares of Akero Therapeutics from $28.00 to $41.00 and gave the stock an overweight rating in a research report on Wednesday, July 1st. Morgan Stanley assumed coverage on shares of Akero Therapeutics in a research report on Thursday, September 10th. They set an overweight rating and a $70.00 price target on the stock. Finally, ValuEngine lowered shares of Akero Therapeutics from a buy rating to a hold rating in a research report on Thursday, July 2nd. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $54.43.

AKRO stock opened at $36.16 on Friday. The stock has a market capitalization of $1.28 billion, a P/E ratio of -17.22 and a beta of 0.46. The firm has a 50-day simple moving average of $34.38 and a 200-day simple moving average of $26.92. Akero Therapeutics has a 52 week low of $10.78 and a 52 week high of $41.16.

Akero Therapeutics (NASDAQ:AKRO) last released its earnings results on Wednesday, August 12th. The company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.09. On average, equities research analysts expect that Akero Therapeutics will post -2.51 earnings per share for the current year.

In other news, major shareholder Global Strategic Fund I. Venbio sold 4,603 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $33.83, for a total value of $155,719.49. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Apple Tree Partners Iv, L.P. purchased 415,000 shares of Akero Therapeutics stock in a transaction dated Friday, July 10th. The stock was bought at an average cost of $36.00 per share, for a total transaction of $14,940,000.00. The disclosure for this purchase can be found here. Insiders own 7.09% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in AKRO. BlackRock Inc. raised its stake in shares of Akero Therapeutics by 33.4% in the 1st quarter. BlackRock Inc. now owns 720,114 shares of the company’s stock valued at $15,267,000 after acquiring an additional 180,215 shares during the period. Victory Capital Management Inc. raised its stake in shares of Akero Therapeutics by 2,010.9% in the 1st quarter. Victory Capital Management Inc. now owns 33,944 shares of the company’s stock valued at $720,000 after acquiring an additional 32,336 shares during the period. American International Group Inc. raised its stake in shares of Akero Therapeutics by 61.9% in the 1st quarter. American International Group Inc. now owns 4,956 shares of the company’s stock valued at $105,000 after acquiring an additional 1,894 shares during the period. Bank of New York Mellon Corp increased its stake in Akero Therapeutics by 44.7% during the 1st quarter. Bank of New York Mellon Corp now owns 27,456 shares of the company’s stock worth $582,000 after buying an additional 8,488 shares during the period. Finally, State Street Corp increased its stake in Akero Therapeutics by 35.0% during the 1st quarter. State Street Corp now owns 118,784 shares of the company’s stock worth $2,518,000 after buying an additional 30,770 shares during the period. 62.99% of the stock is currently owned by institutional investors and hedge funds.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.

Recommended Story: Intrinsic Value and Stock Selection

Analyst Recommendations for Akero Therapeutics (NASDAQ:AKRO)

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.